Interferon alfa therapy in an infant with juvenile chronic myelogenous leukemia

Roberto Toraldo, Francesco Vetrano, Vito Pistoia, Carlo Tolone, Gianfranco Canino, Michele D'Avanzo, Ferdinando Lafusco

Research output: Contribution to journalArticlepeer-review


We describe an infant with juvenile chronic myelogenous leukemia (JCML), the diagnosis of which was made by the characteristic clinical and hematologic findings. The absence of a related HLA - compatible donor for bone marrow transplantation coupled with the awareness that chemotherapy is usually ineffective prompted our decision to treat the patient with lymphoblastoid interferon-α [αLy)-IFN]. During the 26-month course of treatment with αLy)-IFN an incomplete regression of hematologic and clinical findings was achieved. The above results, along with the easy administration and absence of considerable side effects, suggest that αLy)-IFN may be a useful therapeutic tool in patients affected by JCML awaiting bone marrow transplantation.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalPediatric Hematology and Oncology
Issue number2
Publication statusPublished - 1995


  • Interferon-α
  • Juvenile chronic myelogenous leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation


Dive into the research topics of 'Interferon alfa therapy in an infant with juvenile chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this